Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 353-357, April 2008

Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins

  • Robertha C. Howell

      Affiliations

    • Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
  • ,
  • Andrew D. Schweitzer

      Affiliations

    • Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    • Howard Hughes Medical Institute—Medical Fellows Program, Chevy Chase, MD 20815, USA
  • ,
  • Arturo Casadevall

      Affiliations

    • Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    • Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
  • ,
  • Ekaterina A. Dadachova

      Affiliations

    • Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    • Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Tel.: +1 718 405 8485; fax: +1 718 405 8457.

Received 3 December 2007; received in revised form 23 December 2007; accepted 31 December 2007.

Abstract 

Introduction

Melanins are high-molecular-weight pigments that are ubiquitous in nature and can also be synthesized in the laboratory from a variety of precursors. Melanins possess numerous interesting physicochemical characteristics, including electromagnetic radiation absorption properties and ability to chelate metals. We have recently reported that melanin has remarkable ionizing-radiation-shielding properties, possibly because it can interact with photons via Compton scattering. We hypothesized that, if administered internally, melanin could play a beneficial role by scavenging various radionuclides, in addition to radiation shielding.

Methods

Three melanins were synthesized from dopamine, 3,4-dihydroxyphenylalanine (l-Dopa) and a combination of l-cysteine and l-Dopa. For control, synthetic melanin made from tyrosine polymerization (Sigma) was used. Melanins were characterized by elemental analysis. The chemosorption of 111In, 225Ac and 213Bi by melanins was studied at 37°C for up to 48 h.

Results

The C-to-N molar ratios for dopamine, l-Dopa and tyrosine melanins were very close at 7.92, 8.39 and 8.48, respectively, while in mixed l-cysteine/l-Dopa melanin, that ratio was much lower at 3.63. This mixed melanin also contained 22.33% sulfur, thus confirming incorporation of S-containing motifs into its structure. Dopamine, l-Dopa and tyrosine melanins were very similar in their abilities to decrease the activity of 111In, 225Ac and 213Bi and their radioactive daughters in supernatants by >10-fold in comparison with the starting levels, while mixed l-cysteine/l-Dopa melanin was able to chemosorb only 111In.

Conclusions

We have demonstrated that synthetic melanins made of diverse precursors can chemosorb 111In, 213Bi and 225Ac, with dopamine, l-Dopa and tyrosine melanins being the most efficient towards all three of these radionuclides. Such properties of synthetic melanins can contribute to the development of the novel melanin-based radioprotective materials.

Keywords: Melanin, Chemosorption, 225-Actinium, 213-Bismuth, 111-Indium, Radiological attack

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(08)00004-8

doi:10.1016/j.nucmedbio.2007.12.006

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 353-357, April 2008